Take a look at the latest blog post from Dale Yuzuki, published on the Silent Valley Consulting website, about a technology from 2008 to 2011 that was the world’s first “true single molecule sequencer”. You can access the post here. Source ..read more

Several years ago during the publishing of the book about COVID-19 diagnostics, therapeutics and vaccines (“Chaos to Cure”), I registered a business with the state of Maryland called Silent Valley Incorporated. Recently with a change in my work situation at Olink (here’s the announcement a few weeks ago over LinkedIn) I went ahead and made myself available for consulting. The website went live... Source ..read more

Do you listen to podcasts? Would you be interested in learning about how Olink Proteomics’ technology is applied in biomarker discovery, drug discovery, proteogenomics, and routine research into biological mechanisms? If so, here’s the first ‘teaser’ advertisement, and we will be launching the first episode in a week. You can listen to the episode by clicking ‘play’, and subscribe wherever you... Source ..read more

A few weeks ago you read about the depth of the UK BioBank which I called a ‘veritable fountain of discovery’ along with five interesting results and hints of what’s to come in the future. Combining many thousands of individuals where both genomic variation data along with circulating protein data will lead to new understandings of the mechanisms of disease, new protein targets to assist in... Source ..read more

After spending some time in Los Angeles this week visiting a few existing and potential customers for Olink Proteomics, I was able to talk with a few friends about their perspective at this particular juncture in the NGS sequencing field. One of the big questions we discussed is what is needed to push the entire field forward, and a consensus is that it is not in the cost and throughput area... Source ..read more

For a technology that started in 2005 with the first 454 / Roche FLX next-generation sequencing (NGS) platform, followed in 2007 with the Solexa / Illumina Genome Analyzer, and then in 2010 with the Ion Torrent / Life Technologies / Thermo Fisher Scientific Personal Genome Machine (now known as Genexus), the NGS market has grown to be about a $6 Billion market. Single-molecule technologies (aka... Source ..read more

That summer day in 2000 was a memorable one: President Bill Clinton with Prime Minister Tony Blair, then-NHGRI Director Francis Collins, and then-CEO of Celera Craig Venter announcing the draft map of the Human Genome Project. To quote a transcript of the event: The optimism of this event (along with the sequence draft analyses published by the competing NGHRI and Celera groups simultaneously in... Source ..read more

The UK Biobank (abbreviated UKB or UKBB) began in 2006 as a long-term study to investigate the ‘respective contributions of genetic predisposition and environmental exposure (including nutrition, lifestyle, medications etc.) to the development of disease’ per Wikipedia. Over the course of four years (2006 to 2010) 22 collection centers across the United Kingdom those born between 1937 and 1970... Source ..read more

Way back in 2009 I remember the first time my sales manager at RainDance Technologies presented their core technology to a sophisticated group at the US National Institutes of Health, with an introduction to microfluidics. He began by saying “Microfluidics has gotten a poor reputation in the life sciences…” and that was a saying that has stuck with me. Later that same year I struggled to close (in... Source ..read more

Olink started its commercial laboratory in the Boston area in 2016, based upon the Proximity Extension Assay technology and method published in a 2014 PLoS One paper entitled “Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability”. One interesting aspect of this technology (and subsequent iterations) is how the 96-well plate format and the setup of... Source ..read more